IMPROVING animal health will be at the centre of a new £10 million investment in new company, Roslin Technologies.
It is hoped that innovations that improve the health of farmed animals and raise agricultural productivity will be brought to market with the support of the cash injection, that will hopefully develop business opportunities arising from the University of Edinburgh’s animal science research.
The deal will allow researchers to explore the commercial potential of technologies that enable low-cost manufacturing of new medicines using chicken eggs.
The company will also bring to market new veterinary vaccines and tools for diagnosing diseases that affect farmed animals.
Roslin Technologies Ltd was launched to facilitate the commercialisation of research from the University of Edinburgh’s Roslin Institute and Royal (Dick) School of Veterinary Studies.
Chief executive officer of Roslin Technologies and partner in JB Equity, Glen Illing, said: “There is incredible demand for innovations that address desperately needed productivity increases in agriculture.
This investment allows us to deliver a technology pipeline that spans across The Roslin Institute’s core focus on food, environmental security and animal and human health.”
The company is a partnership between the University, the agriculture-focused private equity advisors JB Equity and the British Innovation Fund, a newly-formed fund that invests in leading innovation venture funds and companies from British universities.
An initial fundraising round has recently concluded, securing £10 million from institutional investors.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here